Skip to main content

Advertisement

Table 1 Input parameters

From: Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

Parameters Age (Years) Source(s)/Assumption
  0–2 2–4 5–17 18–64 65+  
Incidence (per 100,000)       
  Bacteremia 14.77 10.62 6.74 43.67 87.07 [18]
  Meningitis 0.52 0.37 0.24 1.54 3.07  
  Inpatient PNE 1,135.13 380.99 170.84 102.76 1,343.40 [1921]
  Outpatient PNE 874.77 460.69 514.63 55.35 63.31  
  Mild AOM 13,762.21 13,811.12 10,486.67 0.00 0.00 [22]
  Moderate/severe AOM 2,147.86 2,155.49 1,636.65 0.00 0.00  
Serotype coverage       
  PCV10 0.18 0.23 0.26 0.28 0.22 [23]
  PCV13 0.61 0.68 0.42 0.55 0.55  
Mortality       
  Bacteremia 0.01 0.003 0.003 0.07 0.11 [2628]
  Meningitis 0.02 0.003 0.003 0.07 0.11  
  Inpatient PNE 0.01 0.003 0.003 0.07 0.11  
Direct medical costs       
  Bacteremia $10,578.71 $3,379.85 $9,768.95 $13,559.64 $11,913.26 [19, 51]
  Meningitis $48,382.04 $24,615.09 $61,114.72 $22,409.11 $11,782.22  
  Inpatient PNE $3,450.13 $2,149.73 $10,305.00 $9,606.02 $8,370.61  
  Outpatient PNE $138.18 $69.09 $184.24 $126.66 $103.63  
  Mild AOM $95.30 $47.65 $71.47 $0.00 $0.00  
  Moderate/severe AOM $95.30 $47.65 $71.47 $0.00 $0.00  
Utilities 0.97 0.97 0.97 0.88 0.82 [54]
  1. AOM acute otitis media; PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; PNE pneumonia.